Niagen Bioscience, Inc. Reports First Quarter 2026 Financial Results

Stock Information for Niagen Bioscience Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Niagen Bioscience Inc.

Niagen Bioscience Announces Participation in Upcoming Investor Conferences
Niagen Bioscience Launches Niagen Plus Telehealth Platform, Unveiling At-Home Injection Kit Offering
Niagen Bioscience Adds Olympia Pharmaceuticals to 503B Compounding Partner Network for Niagen Plus(TM)
Niagen Bioscience to Report First Quarter 2026 Financial Results on Wednesday, May 6, 2026
Niagen Bioscience Collaborates with USP to Establish First-Ever USP Monograph for Nicotinamide Riboside Chloride (NRCl), the Patented Form in Niagen®
Niagen Bioscience Announces First Cruise Ship Clinic Partnership with OneSpaWorld, Bringing the NAD-Boosting Benefits of Niagen IV to the High Seas
Niagen Bioscience Increases Share Repurchase Program to $20 Million
Niagen Bioscience to Present at the 38th Annual ROTH Conference

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.